<?xml version="1.0" encoding="UTF-8"?>
<p id="par0035">The term “cytokine release syndrome” appeared in the early ‘90 s, when the anti T-cell antibody muromonab-CD3 was introduced as an immunosuppressive treatment for solid organ transplantation [
 <xref rid="bib0020" ref-type="bibr">4</xref>]. Yet, Vegh et al. as early as in 1975 observed that by administering polyclonal antibodies the possibility of systemic anaphylactic reactions and other side effects may be present [
 <xref rid="bib0025" ref-type="bibr">5</xref>]. Presumably they supposed a cytokine-storm like reaction which has different phenotypes from the classical type-I or complement-mediated reaction. At that time such biomarkers as tryptase, IL-6, bradykinin etc. were not known or were on the early stages of immunological research [
 <xref rid="bib0030" ref-type="bibr">6</xref>].
</p>
